secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001193125-23-164459
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics stockholders elect three Class I directors and ratify PwC as auditor
--------------------------------------------------------------------------------

- Elected Kabeer Aziz (14.78M for), Gilbert Lynn Marks (14.78M for), and Rob Readnour (14.61M for) as Class I directors.
- Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2023: 16.56M for, 51.6K against.
- Quorum of 16,610,548 shares (85.5% of outstanding) present at June 7, 2023 annual meeting.
- Results based on proxy statement filed April 26, 2023; no other proposals voted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/0001193125-23-164459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/d500763d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer